Literature DB >> 21536859

ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.

Julie A I Thoms1, Yehudit Birger, Sam Foster, Kathy Knezevic, Yael Kirschenbaum, Vashe Chandrakanthan, Georg Jonquieres, Dominik Spensberger, Jason W Wong, S Helen Oram, Sarah J Kinston, Yoram Groner, Richard Lock, Karen L MacKenzie, Berthold Göttgens, Shai Izraeli, John E Pimanda.   

Abstract

The Ets-related gene (ERG) is an Ets-transcription factor required for normal blood stem cell development. ERG expression is down-regulated during early T-lymphopoiesis but maintained in T-acute lymphoblastic leukemia (T-ALL), where it is recognized as an independent risk factor for adverse outcome. However, it is unclear whether ERG is directly involved in the pathogenesis of T-ALL and how its expression is regulated. Here we demonstrate that transgenic expression of ERG causes T-ALL in mice and that its knockdown reduces the proliferation of human MOLT4 T-ALL cells. We further demonstrate that ERG expression in primary human T-ALL cells is mediated by the binding of other T-cell oncogenes SCL/TAL1, LMO2, and LYL1 in concert with ERG, FLI1, and GATA3 to the ERG +85 enhancer. This enhancer is not active in normal T cells but in transgenic mice targets expression to fetal liver c-kit(+) cells, adult bone marrow stem/progenitors and early CD4(-)CD8(-) double-negative thymic progenitors. Taken together, these data illustrate that ERG promotes T-ALL and that failure to extinguish activity of stem cell enhancers associated with regulatory transcription factors such as ERG can contribute to the development of leukemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536859     DOI: 10.1182/blood-2010-12-317990

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 2.  Developmental gene networks: a triathlon on the course to T cell identity.

Authors:  Mary A Yui; Ellen V Rothenberg
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

3.  MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Authors:  Y Huang; J A I Thoms; M L Tursky; K Knezevic; D Beck; V Chandrakanthan; S Suryani; J Olivier; A Boulton; E N Glaros; S R Thomas; R B Lock; K L MacKenzie; J H Bushweller; J W H Wong; J E Pimanda
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

4.  Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.

Authors:  K Nowek; S M Sun; L Bullinger; E M J Bindels; C Exalto; M K Dijkstra; K van Lom; H Döhner; S J Erkeland; B Löwenberg; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

5.  A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.

Authors:  Ashwin Unnikrishnan; Yi F Guan; Yizhou Huang; Dominik Beck; Julie A I Thoms; Sofie Peirs; Kathy Knezevic; Shiyong Ma; Inge V de Walle; Ineke de Jong; Zara Ali; Ling Zhong; Mark J Raftery; Tom Taghon; Jonas Larsson; Karen L MacKenzie; Pieter Van Vlierberghe; Jason W H Wong; John E Pimanda
Journal:  Nucleic Acids Res       Date:  2016-09-06       Impact factor: 16.971

6.  Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq.

Authors:  Karen M Mann; Justin Y Newberg; Michael A Black; Devin J Jones; Felipe Amaya-Manzanares; Liliana Guzman-Rojas; Takahiro Kodama; Jerrold M Ward; Alistair G Rust; Louise van der Weyden; Christopher Chin Kuan Yew; Jill L Waters; Marco L Leung; Keith Rogers; Susan M Rogers; Leslie A McNoe; Luxmanan Selvanesan; Nicholas Navin; Nancy A Jenkins; Neal G Copeland; Michael B Mann
Journal:  Nat Biotechnol       Date:  2016-08-01       Impact factor: 54.908

7.  Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.

Authors:  Ying Xie; Mia Lee Koch; Xin Zhang; Melanie J Hamblen; Frank J Godinho; Yuko Fujiwara; Huafeng Xie; Jan-Henning Klusmann; Stuart H Orkin; Zhe Li
Journal:  Stem Cells       Date:  2017-04-24       Impact factor: 6.277

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Authors:  Yehudit Birger; Liat Goldberg; Timothy M Chlon; Benjamin Goldenson; Inna Muler; Ginette Schiby; Jasmin Jacob-Hirsch; Gideon Rechavi; John D Crispino; Shai Izraeli
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

Review 10.  Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.

Authors:  N C Correia; M-L Arcangeli; F Pflumio; J T Barata
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.